Evidence map›Paper›PMID 37287996›Full record

ArticleCannabis (Albuquerque, N.M.)2021

Hair Regrowth with Cannabidiol (CBD)-rich Hemp Extract - A Case Series.

Gregory L Smith, John Satino

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Cannabis (Albuquerque, N.M.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04842383 (Androgenetic Alopecia Treatment Using Varin and Cannabidiol-rich Topical Hemp Oil - A Case Series), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04842383 early_phase1unknown statusnot on this map

Androgenetic Alopecia Treatment Using Varin and Cannabidiol-rich Topical Hemp Oil - A Case Series

TypeinterventionalSponsorGregory L Smith, MD, MPHRan2021 to 2021Enrolled40ConditionsAndrogenetic AlopeciaArmsHemp Oil
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Hemp (International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Effects of a Cannabinoid-Based Phytocomplex (Pain ReliefAnimals : an open access journal from MDPI · 2025
    Article
  5. Review
  6. Review
  7. Cannabinoids and Their Receptors in Skin Diseases.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gregory L SmithMedical Director, Medical Life Care Planners, St. Petersburg, FL, USA.
John SatinoLaser Hair Center, Clearwater, FL, USA.
Clinical Research Center for Hair and Skin Science · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgenetic alopecia (AGA) is the most common cause of hair loss. Several FDA approved medications are available but offer limited results. Studies have shown that the endocannabinoid system (ECS) is a key player in hair follicle cell growth. The ECS cannabinoid type one (CB1) receptors are well expressed in the hair follicle cells. Cannabidiol CBD is a negative allosteric modulator of the CB1 receptor and has been shown to result in hair shaft elongation. In addition, the hair follicle cycle phases are controlled by the ECS vanilloid receptor-1 (TRPV1). CBD has also been shown to increase Wnt signaling pathways that are involved in the differentiation of dermal progenitor cells into new hair follicles and maintaining the anagen phase of the hair cycle. The effects of CBD on hair growth are dose dependent and higher doses may result in premature entry into the catagen phase via a receptor known as vanilloid receptor-4 (TRPV4). Topical application of CBD reaches hair follicles where it is a CB1 negative modulator, and TRPV1, and TRPV4 agonist. A study was done of 35 subjects with AGA using a once daily topical hemp oil formulation, averaging about 3-4 mg per day of CBD and minimal amounts of other cannabinoids for six months. A hair count of the greatest area of alopecia was carried out before treatment and again after six months. The results revealed that men did slightly better than women, and the vertex area did better than the temporal areas. On average there was statistically significant 93.5% increase in hair after 6 months. All subjects had some regrowth. There were no reported adverse effects. Since the CBD works through novel mechanisms different from finasteride and minoxidil it can be used in conjunction with these current drugs and would be expected to have synergistic effects.

Indexed as

androgenetic alopecia (ACA)= cannabidiol (CBD)cannabinoid one receptor (CB1)vanilloid receptor-1 (TRPV1)

Identifiers

PMID37287996
PMCPMC10212262
OpenAlexW3135812860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.